CT-388 is the only dual GLP-1R/GIPR agonist in development with near-perfect balanced potency at both receptors
Tirzepatide (Zepbound) injection
Thousands of members and counting Real members, real weight loss results Don't just take it from usour members see (and feel) the difference
Room Temperature Storage Limitations and Risks While some peptide compounds tolerate brief periods at room temperature, Retatrutide Powder demonstrates limited stability outside controlled cold storage environments, making room temperature storage inadvisable for extended durations
The combination might therefore enhance feelings of fullness and support adherence to reduced-calorie dietary patterns, which are fundamental to successful weight management, though individual responses may vary considerably
GI adaptation: Lower doses allow the digestive system to adjust, reducing nausea and vomiting Triple receptor activation: Retatrutide's unique GLP-1/GIP/glucagon mechanism requires gradual introduction Safety monitoring: Assess individual response before increasing to therapeutic doses Injection site tolerance: Verify no local reactions before committing to higher doses What to Expect in the First Week During the initial retatrutide dose, you may experience: Mild appetite reduction (typically noticeable by days 2-3) Possible nausea, especially with large or fatty meals Minor injection site reaction (redness, mild swelling) Increased satiety after smaller portions Important: Don't be discouraged if you don't see significant weight loss at 2mg
